Projects a measured vancomycin concentration to the end of the dosing interval. This guide explains the pharmacokinetic source, assumptions, safe unit handling, interpretation, monitoring and limitations.
Overview
Projects a measured vancomycin concentration to the end of the dosing interval.
Clinical Significance
The calculation estimates the concentration immediately before the next dose but should not substitute for AUC-guided assessment where indicated.
When to Use
- Use when the required concentration, timing and dosing information are reliable and the stated pharmacokinetic assumptions are reasonable.
- Use within an approved therapeutic-drug-monitoring or medicines-governance pathway.
- Use to support transparent review, not to automate prescribing.
How It Is Calculated
- C(trough) = C(measured) × e^[−k × (interval − sample time)].
- MedicalC validates that all required inputs are numeric and rejects internally impossible time or concentration relationships where applicable.
Interpretation
- The calculation estimates the concentration immediately before the next dose but should not substitute for AUC-guided assessment where indicated.
- Interpret the result with the clinical indication, microbiology or seizure control, organ function, assay timing and local targets.
Worked Example
Enter a verified set of source values in the displayed units. MedicalC applies: C(trough) = C(measured) × e^[−k × (interval − sample time)]. Recheck the source chart and sampling times before using the result.
Patient Considerations
- Primarily intended for adults receiving intermittent intravenous vancomycin. Paediatrics, pregnancy, obesity, augmented renal clearance, dialysis, extracorporeal support, burns and unstable renal function require specialist methods.
- Consider acute kidney injury, augmented renal clearance, fluid shifts, obesity, burns, pregnancy, critical illness and interacting medicines.
Limitations
- One-compartment equations may not describe distribution or multicompartment behaviour accurately.
- Derived values can appear precise despite uncertainty in sampling time, assay result and clearance stability.
- A calculated exposure or dose does not establish clinical benefit or safety.
Clinical Pearls
- Trough concentration and AUC are related but not interchangeable; identical troughs can correspond to materially different AUC exposures.
- Plot concentrations against actual elapsed time before accepting any pharmacokinetic slope.
- When the result conflicts with the patient, verify the data rather than forcing a dose change.
Common Mistakes
- Using scheduled rather than actual administration and blood-sampling times.
- Treating a level drawn during distribution as a post-distribution concentration.
- Mixing mg/L, micrograms/mL and micrograms/L.
- Applying steady-state equations before steady state or during changing clearance.
- Using a generic concentration target outside the relevant indication or local protocol.
Evidence Base
Principal source: Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: revised consensus guideline. Am J Health Syst Pharm. 2020.
Frequently Asked Questions
What does the Vancomycin Projected Trough Concentration calculator estimate?
Projects a measured vancomycin concentration to the end of the dosing interval.
Can this result be used to prescribe automatically?
No. It requires clinician and pharmacist interpretation within a drug-specific protocol.
Why do actual administration and sample times matter?
Small timing errors can materially change an elimination slope, projected concentration or calculated exposure.
What should be checked after using the result?
Reassess renal function, dosing history, infusion and sample times, concomitant nephrotoxins, microbiology and repeat concentrations. Use an approved AUC workflow where available.
When is a direct or Bayesian method preferable?
Use a validated Bayesian platform or direct free-level measurement when recommended, especially in complex or unstable patients.
References
- Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: revised consensus guideline. Am J Health Syst Pharm. 2020. — Primary publication, consensus guideline or authoritative pharmacokinetic source.
Reviewed by: MedicalC Clinical Editorial Team
Last reviewed: July 2026
